Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    October 2017
  1. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
    Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
    PubMed     Text format     Abstract available


  2. FABER AC, Song KA, Niederst MJ, Lochmann TL, et al
    Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.
    Clin Cancer Res. 2017 Oct 19. pii: clincanres.1577.2017.
    PubMed     Text format     Abstract available


  3. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Text format     Abstract available


  4. WANG Y, Gudikote J, Giri U, Yan J, et al
    RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1455.2017.
    PubMed     Text format     Abstract available


  5. LOHAVANICHBUTR P, Sakoda LC, Amos CI, Arnold SM, et al
    Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.1401.2017.
    PubMed     Text format     Abstract available


    September 2017
  6. HU X, Liu T, Wu X, Chen T, et al
    Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/beta-catenin signaling.
    Clin Cancer Res. 2017 Sep 28. pii: clincanres.1169.2017.
    PubMed     Text format     Abstract available


  7. YI JS, Ready N, Healy P, Dumbauld C, et al
    Immune Activation in Early Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.2005.2017.
    PubMed     Text format     Abstract available


  8. FENG Y, Wang X, Bajaj G, Agrawal S, et al
    Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017;23:5394-5405.
    PubMed     Text format     Abstract available


  9. GU L, Deng JZ, Roy S, Hammond PT, et al
    A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.2186.2016.
    PubMed     Text format     Abstract available


    August 2017
  10. OOKI A, Maleki Z, Tsay JJ, Goparaju CM, et al
    A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.1222.2017.
    PubMed     Text format     Abstract available



  11. Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
    Clin Cancer Res. 2017;23:4523.
    PubMed     Text format    


  12. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
    PubMed     Text format     Abstract available


    July 2017
  13. SEN T, Tong P, Diao L, Li L, et al
    Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer.
    Clin Cancer Res. 2017 Jul 11. pii: clincanres.1284.2017.
    PubMed     Text format     Abstract available


  14. GRAY JE, Heist RS, Starodub AN, Camidge DR, et al
    Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0933.2017.
    PubMed     Text format     Abstract available


  15. NISHINO M, Dahlberg SE, Adeni AE, Lydon C, et al
    Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.1434.2017.
    PubMed     Text format     Abstract available


  16. ADAMS DL, Adams DK, He J, Kalhor N, et al
    Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0802.2017.
    PubMed     Text format     Abstract available


    June 2017
  17. MALCHERS F, Ercanoglu MS, Schutte D, Castiglione R, et al
    Mechanisms of primary drug resistance in FGFR1 amplified lung cancer.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0478.2017.
    PubMed     Text format     Abstract available


  18. WEINSTOCK C, Khozin S, Suzman D, Zhang L, et al
    U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0540.2017.
    PubMed     Text format     Abstract available


  19. JIN X, Chen Y, Chen H, Fei S, et al
    Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early stage non-small-cell lung cancer using next-generation sequencing.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0577.2017.
    PubMed     Text format     Abstract available


    May 2017
  20. CASCONE T, Xu L, Lin HY, Liu W, et al
    The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer.
    Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016.
    PubMed     Text format     Abstract available


  21. JEONG J, Oh JH, Sonke JJ, Belderbos JSA, et al
    Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.
    Clin Cancer Res. 2017 May 24. pii: clincanres.3277.2017.
    PubMed     Text format     Abstract available


  22. LEE JMM, Lee MH, Garon E, Goldman JW, et al
    Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration.
    Clin Cancer Res. 2017 May 3. pii: clincanres.2821.2016.
    PubMed     Text format     Abstract available


    April 2017
  23. COOPER WA, Russell PA, Cherian M, Duhig EE, et al
    Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC).
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017.
    PubMed     Text format     Abstract available


  24. LI AN, Yang J, Zhang XC, Zhang Z, et al
    Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
    PubMed     Text format     Abstract available


    March 2017
  25. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
    Clin Cancer Res. 2017 Mar 16. doi: 10.1158/1078-0432.CCR-16-1946.
    PubMed     Text format     Abstract available


    February 2017
  26. LAKSHMANAN I, Salfity S, Seshacharyulu P, Rachagani S, et al
    MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.2530.2016.
    PubMed     Text format     Abstract available


  27. VAN DER WEKKEN A, Pelgrim R, 't Hart N, Werner N, et al
    Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer.
    Clin Cancer Res. 2017 Feb 9. pii: clincanres.1631.2016.
    PubMed     Text format     Abstract available


    January 2017
  28. BONANNO L, De Paoli A, Zulato E, Esposito G, et al
    LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab.
    Clin Cancer Res. 2017 Jan 24. pii: clincanres.2410.2016.
    PubMed     Text format     Abstract available


  29. RATCLIFFE MJ, Sharpe A, Midha A, Barker C, et al
    Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2375.2016.
    PubMed     Text format     Abstract available


    December 2016
  30. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    GENOMIC PROFILING OF PATIENT-DERIVED XENOGRAFTS FOR LUNG CANCER IDENTIFIES B2M INACTIVATION IMPAIRING IMMUNORECOGNITION.
    Clin Cancer Res. 2016 Dec 21. pii: clincanres.1946.2016.
    PubMed     Text format     Abstract available


  31. TANIMOTO A, Takeuchi S, Arai S, Fukuda K, et al
    Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib-resistance in EGFR-mutant lung cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2271.2016.
    PubMed     Text format     Abstract available


  32. XUE Y, Lito P
    Predicting MEK inhibitor response in lung cancer: a proper signature is required.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.2576.2016.
    PubMed     Text format     Abstract available


  33. KHOZIN S, Weinstock C, Blumenthal GM, Cheng J, et al
    Osimertinib for the Treatment of Metastatic Epidermal Growth Factor T970M Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1773.2016.
    PubMed     Text format     Abstract available


    November 2016
  34. LIU G, Cuffe S, Liang S, Azad AK, et al
    BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1640.2016.
    PubMed     Text format     Abstract available


  35. SKOULIDIS F, Papadimitrakopoulou VA
    Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-small Cell Lung Cancer.
    Clin Cancer Res. 2016 Nov 7. pii: clincanres.2815.2015.
    PubMed     Text format     Abstract available


  36. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


  37. SKOULIDIS F, Papadimitrakopoulou VA
    Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
    Clin Cancer Res. 2016;22:5177-5182.
    PubMed     Text format     Abstract available


    October 2016
  38. HULBERT A, Jusue Torres I, Stark A, Chen C, et al
    Early Detection of Lung Cancer using DNA Promoter Hypermethylation in Plasma and Sputum.
    Clin Cancer Res. 2016 Oct 11. pii: clincanres.1371.2016.
    PubMed     Text format     Abstract available


  39. RAMALINGAM SS, Blais N, Mazieres J, Reck M, et al
    Randomized, Placebo-Controlled, Phase 2 Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.3069.2016.
    PubMed     Text format     Abstract available


    September 2016
  40. GEORGE J, Saito M, Tsuta K, Iwakawa R, et al
    Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.1069.2016.
    PubMed     Text format     Abstract available


  41. THOMPSON JC, Yee SS, Troxel AB, Savitch SL, et al
    Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1231.2016.
    PubMed     Text format     Abstract available


  42. ZHOU W, Xu J, Li H, Xu M, et al
    Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage.
    Clin Cancer Res. 2016 Sep 2. pii: clincanres.1585.2016.
    PubMed     Text format     Abstract available


    August 2016
  43. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.3071.2015.
    PubMed     Text format     Abstract available


  44. MECKLENBURG I, Sienel W, Schmid S, Passlick B, et al
    A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung cancer.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.0557.2016.
    PubMed     Text format     Abstract available


    July 2016
  45. GETTINGER S, Politi K
    PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause?
    Clin Cancer Res. 2016 Jul 28. pii: clincanres.1401.2016.
    PubMed     Text format     Abstract available


  46. LOK BH, Gardner EE, Schneeberger VE, Ni A, et al
    PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.1040.2016.
    PubMed     Text format     Abstract available


  47. SCHALPER KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, et al
    Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0150.2016.
    PubMed     Text format     Abstract available


  48. LARKINS E, Blumenthal GM, Chen H, He K, et al
    FDA Approval: Alectinib for the Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
    Clin Cancer Res. 2016 Jul 13. pii: clincanres.1293.2016.
    PubMed     Text format     Abstract available


  49. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
    Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.1601.2015.
    PubMed     Text format     Abstract available


    June 2016
  50. WANG Y, Liu H, Diao L, Potter A, et al
    Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2190.2015.
    PubMed     Text format     Abstract available


  51. GIRARD L, Rodriguez-Canales J, Behrens C, Thompson DM, et al
    An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2900.2015.
    PubMed     Text format     Abstract available


  52. YANAGITA M, Redig AJ, Paweletz CP, Dahlberg SE, et al
    A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016.
    PubMed     Text format     Abstract available


  53. WANG E, Nickens DJ, Bello A, Khosravan R, et al
    Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016.
    PubMed     Text format     Abstract available


  54. HAMILTON DH, Matthews Griner L, Keller JM, Hu X, et al
    Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3059.2015.
    PubMed     Text format     Abstract available


  55. GAPONOVA AV, Nikonova A, Deneka AY, Kopp MC, et al
    A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC).
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3068.2015.
    PubMed     Text format     Abstract available


  56. SIVA S, Lobachevsky PN, MacManus M, Kron T, et al
    Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues.
    Clin Cancer Res. 2016 Jun 3. pii: clincanres.0138.2016.
    PubMed     Text format     Abstract available


  57. PARRA ER, Behrens C, Rodriguez-Canales J, Lin HY, et al
    Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.2443.2015.
    PubMed     Text format     Abstract available


  58. MORGENSZTERN D, Herbst RS
    Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.2998.2016.
    PubMed     Text format     Abstract available


    May 2016
  59. GAINOR JF, Shaw AT, Sequist LV, Fu X, et al
    EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis.
    Clin Cancer Res. 2016 May 25. pii: clincanres.3101.2015.
    PubMed     Text format     Abstract available


  60. TANG KJ, Constanzo J, Venkateswaran N, Melegari M, et al
    Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
    Clin Cancer Res. 2016 May 24. pii: clincanres.2603.2015.
    PubMed     Text format     Abstract available


    April 2016
  61. NILSSON MB, Giri U, Gudikote J, Tang X, et al
    KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
    Clin Cancer Res. 2016;22:1940-50.
    PubMed     Text format     Abstract available


  62. SHARMA A, Bender S, Zimmermann M, Riesterer O, et al
    Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2449.2015.
    PubMed     Text format     Abstract available


  63. DATAR I, Schalper KA
    Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.0336.2016.
    PubMed     Text format     Abstract available


  64. CORTOT AB, Moro-Sibilot D, Cadranel J
    Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter.
    Clin Cancer Res. 2016;22:1827.
    PubMed     Text format    


    March 2016
  65. DRILON A
    MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
    Clin Cancer Res. 2016 Mar 23. pii: clincanres.0229.2016.
    PubMed     Text format     Abstract available


  66. KAZANDJIAN D, Blumenthal GM, Yuan W, He K, et al
    FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016;22:1307-12.
    PubMed     Text format     Abstract available


    February 2016
  67. RODRIGUEZ PC, Popa X, Martinez O, Mendoza S, et al
    A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer Patients.
    Clin Cancer Res. 2016 Feb 29. pii: clincanres.0855.2015.
    PubMed     Text format     Abstract available


  68. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Clin Cancer Res. 2016;22:923-34.
    PubMed     Text format     Abstract available


  69. REDIG AJ, Capelletti M, Dahlberg SE, Sholl LM, et al
    Clinical and molecular characteristics of NF1 mutant lung cancer.
    Clin Cancer Res. 2016 Feb 9. pii: clincanres.2377.2015.
    PubMed     Text format     Abstract available


  70. TONG JH, Yeung SF, Chan AW, Chung LY, et al
    MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-small Cell Lung Carcinoma with poor prognosis.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.2061.2015.
    PubMed     Text format     Abstract available


  71. DIAZ-LAGARES A, Mendez-Gonzalez J, Hervas D, Saigi M, et al
    A novel epigenetic signature for early diagnosis in lung cancer.
    Clin Cancer Res. 2016 Feb 3. pii: clincanres.2346.2015.
    PubMed     Text format     Abstract available


    January 2016
  72. TERASHIMA M, Togashi Y, Sato K, Mizuuchi H, et al
    Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2.
    Clin Cancer Res. 2016 Jan 29. pii: clincanres.2093.2015.
    PubMed     Text format     Abstract available


  73. GREEN H, Hasmats J, Kupershmidt I, Edsgard D, et al
    Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
    Clin Cancer Res. 2016;22:366-73.
    PubMed     Text format     Abstract available


  74. PIRAZZOLI V, Ayeni D, Meador CB, Sanganahalli BG, et al
    Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma.
    Clin Cancer Res. 2016;22:426-35.
    PubMed     Text format     Abstract available


  75. TAO Z, Le Blanc JM, Wang C, Zhan T, et al
    Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Clin Cancer Res. 2016;22:122-33.
    PubMed     Text format     Abstract available


    December 2015
  76. DRILON A, Somwar R, Wagner JP, Vellore NA, et al
    A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.2013.2015.
    PubMed     Text format     Abstract available


  77. GOVINDAN R, Mandrekar SJ, Gerber DE, Oxnard GR, et al
    ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015;21:5439-5444.
    PubMed     Text format     Abstract available


  78. TSUI DW, Berger MF
    Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.2514.2015.
    PubMed     Text format     Abstract available


  79. BELL EH, Chakraborty AR, Mo X, Liu Z, et al
    SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.1468.2015.
    PubMed     Text format     Abstract available


  80. MANSFIELD AS, Murphy SJ, Peikert T, Yi ES, et al
    Heterogeneity of programmed cell death-ligand 1 expression in multifocal lung cancer.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.2246.2015.
    PubMed     Text format     Abstract available


  81. GORGES TM, Penkalla N, Schalk T, Joosse S, et al
    Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.1416.2015.
    PubMed     Text format     Abstract available


  82. LEE JY, Sun JM, Lim SH, Kim H, et al
    A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.1653.2015.
    PubMed     Text format     Abstract available


  83. LI J, Ye C, Mansmann UR
    Comparing patient-derived xenograft and computational response prediction for targeted therapy in patients of early-stage large cell lung cancer.
    Clin Cancer Res. 2015 Dec 4. pii: clincanres.2401.2015.
    PubMed     Text format     Abstract available


  84. IAFRATE AJ
    CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors.
    Clin Cancer Res. 2015;21:5185-7.
    PubMed     Text format     Abstract available


    November 2015
  85. FERRAROTTO R, Goonatilake R, Yoo SY, Tong P, et al
    Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015 Nov 23. pii: clincanres.2890.2014.
    PubMed     Text format     Abstract available


    June 2015
  86. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


  87. CESCON DW, She D, Sakashita S, Zhu CQ, et al
    NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
    Clin Cancer Res. 2015;21:2499-505.
    PubMed     Text format     Abstract available


  88. CHOI S, Kim HR, Sung CO, Kim J, et al
    Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.
    Clin Cancer Res. 2015;21:2613-23.
    PubMed     Text format     Abstract available


  89. COLLISSON EA
    RB and Prognosis in Resected Lung Adenocarcinoma.
    Clin Cancer Res. 2015;21:2418-20.
    PubMed     Text format     Abstract available


    May 2015
  90. BATES SE
    Quit early, quit often.
    Clin Cancer Res. 2015;21:2212.
    PubMed     Text format    


    April 2015
  91. ARCILA ME, Drilon A, Sylvester BE, Lovly CM, et al
    MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
    Clin Cancer Res. 2015;21:1935-43.
    PubMed     Text format     Abstract available


    March 2015
  92. STARMANS MH, Pintilie M, Chan-Seng-Yue M, Moon NC, et al
    Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
    Clin Cancer Res. 2015;21:1477-86.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: